Zoetis raises 2026 adjusted EPS outlook to $6.25–$6.35
U.S. companion-animal revenue fell 8%, while international livestock revenue increased 8% during the quarter.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
8-K
Rhea-AI Filing Summary
Zoetis Inc. (ZTS) reported third-quarter 2026 revenue of $2.391 billion, down 1% year over year. Net income fell 18% to $591 million and diluted EPS fell 12% to $1.44. Adjusted net income was $720 million, down 5%, while adjusted diluted EPS rose 3% to $1.75; both adjusted measures are non-GAAP.
U.S. revenue declined 6% to $1.246 billion, including an 8% drop in companion-animal revenue; international revenue increased 4% to $1.116 billion. Livestock revenue increased 5% in the U.S. and 8% internationally. For full-year 2026, Zoetis raised adjusted net income guidance to $2.600 billion–$2.640 billion and adjusted diluted EPS to $6.25–$6.35, and narrowed revenue guidance to $9.220 billion–$9.320 billion.
The FDA approved Convenia RTU for Dogs in October, with availability expected in the first quarter of 2027. Simparica Trio received U.S. FDA Emergency Use Authorization for New World screwworm infestations in dogs and puppies.
0 points · 0 major0 major · 1 point
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Positive
- None.
Negative
- Moderate pointThird-quarter net income fell 18% to $591 million; diluted EPS fell 12% to $1.44.
Filing Explained
For 2026, Zoetis’s reported diluted EPS guidance is
8-K Event Classification
2 items: 2.02, 9.01
2 items
Item 2.02
Results of Operations and Financial Condition
Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
Revenue: $2.391 billion
Net income: $591 million
Diluted EPS: $1.44 per share
+4 more
7 metrics
Revenue
$2.391 billion
Third quarter 2026; down 1% reported and organic operational year over year
Net income
$591 million
Third quarter 2026; down 18% reported year over year
Diluted EPS
$1.44 per share
Third quarter 2026; down 12% reported year over year
Adjusted net income
$720 million
Third quarter 2026; down 5% reported and 7% organic operational year over year
Adjusted diluted EPS
$1.75 per share
Third quarter 2026; up 3% reported and 1% organic operational year over year
Full-year revenue guidance
$9.220 billion to $9.320 billion
2026 guidance as of November 5, 2026
Full-year adjusted diluted EPS guidance
$6.25 to $6.35 per share
2026 guidance as of November 5, 2026; raised
Key Terms
organic operational results, adjusted diluted EPS, Emergency Use Authorization (EUA), purchase accounting adjustments
4 terms
organic operational results financial
"Organic operational results (a non-GAAP financial measure) is defined as results excluding"
adjusted diluted EPS financial
"Adjusted diluted EPS was $1.75, increasing 3% on a reported basis"
Adjusted diluted EPS is a company’s profit per share after adding back or removing one-time items (like restructuring costs or gains) and dividing by the number of shares including potential shares from options and convertible securities. Investors use it as a cleaner view of ongoing earnings—like looking at a car’s regular fuel efficiency rather than a trip boosted by downhill coasting—to judge underlying performance and compare companies without temporary distortions.
Emergency Use Authorization (EUA) regulatory
"received U.S. FDA Emergency Use Authorization (EUA)"
purchase accounting adjustments financial
"excluding purchase accounting adjustments, acquisition and divestiture-related costs"
Purchase accounting adjustments are one-time changes made to a company’s financial statements after it buys another business, reallocating the purchase price to the acquired assets and liabilities at their fair values. Like re-appraising a house and its contents after a sale, these adjustments can shift reported assets, liabilities and future profit figures, so investors watch them because they affect balance sheets, reported earnings and comparisons with past performance.
Earnings Snapshot
Revenue: $2.391 billion · Guidance included
Third quarter 2026
Revenue
$2.391 billion
Down 1% reported and organic operational
Net income
$591 million
Down 18% reported
Diluted EPS
$1.44 per share
Down 12% reported
Adjusted net income
$720 million
Down 5% reported and 7% organic operational
Adjusted diluted EPS
$1.75 per share
Up 3% reported and 1% organic operational
Guidance
Full-year 2026 revenue: $9.220 billion to $9.320 billion; adjusted net income: $2.600 billion to $2.640 billion; adjusted diluted EPS: $6.25 to $6.35.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What were ZTS's third-quarter 2026 revenue and net income?
Zoetis reported revenue of $2.391 billion, down 1% reported and organic operational from the year-ago quarter, and net income of $591 million, down 18% reported. Diluted EPS was $1.44, down 12% reported.
What is Zoetis' full-year 2026 guidance?
Revenue guidance is $9.220 billion to $9.320 billion, with organic operational growth of (2)% to (1)%. Adjusted net income guidance is $2.600 billion to $2.640 billion, with organic operational growth of (7)% to (5)%; adjusted diluted EPS guidance is $6.25 to $6.35.
When is Convenia RTU for Dogs expected to be available?
Convenia RTU for Dogs, approved by the FDA in October, is expected to be available to veterinarians in the first quarter of 2027.
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
| FORM | |||||
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): November 5, 2026
| (Exact name of registrant as specified in its charter) | ||
| (State or other jurisdiction | (Commission File | (I.R.S. Employer | ||||||||||||
| of incorporation) | Number) | Identification No.) | ||||||||||||
| (Address of principal executive offices) | (Zip Code) | |||||||||||||
(973 ) 822-7000
| (Registrant's telephone number, including area code) | ||
| Not Applicable | ||
| (Former Name or Former Address, if changed since last report) | ||
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition
On November 5, 2026, Zoetis Inc. (the Company) issued a press release reporting its financial results for the third quarter of 2026 and its guidance for full year 2026. A copy of the Company’s press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information in this Item 2.02 and the attached Exhibit 99.1 is being furnished to the Securities and Exchange Commission and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
| Exhibit No. | Description | ||||
99.1 | Press Release of Zoetis Inc. dated November 5, 2026, reporting Zoetis' financial results for the | ||||
third quarter of 2026 and its guidance for full year 2026. | |||||
| EX-101.INS | Inline XBRL INSTANCE DOCUMENT | ||||
| EX-101.SCH | Inline XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT | ||||
| EX-101.CAL | Inline XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT | ||||
| EX-101.LAB | Inline XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT | ||||
| EX-101.PRE | Inline XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT | ||||
| EX-101.DEF | Inline XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT | ||||
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) | ||||
SIGNATURE
Under the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the authorized undersigned.
| Zoetis Inc. | ||||||||
November 5, 2026 | By: | /S/ JAY SACCARO | ||||||
| Jay Saccaro | ||||||||
| Executive Vice President, Chief Financial Officer and Chief Operating Officer | ||||||||
EXHIBIT 99.1
Zoetis Announces Third Quarter 2026 Results; Highlights Progress Advancing Innovation Across Diversified Portfolio and Narrows Full Year 2026 Revenue Guidance, Raises Full Year 2026 Adjusted EPS Guidance
Third Quarter 2026 Highlights
•Revenue: $2.4 billion, decreased 1% reported and organic operational1
◦U.S. segment revenue: $1.2 billion, decreased 6% reported and organic operational
◦International segment revenue: $1.1 billion, increased 4% reported and organic operational basis
•Net Income: $591 million, decreased 18% reported
•Adjusted net income: $720 million, decreased 5% reported and 7% organic operational
•Diluted EPS: $1.44, decreased 12% reported
•Adjusted diluted EPS: $1.75, increased 3% reported and 1% organic operational
PARSIPPANY, N.J. – November 5, 2026 – Zoetis Inc. (NYSE:ZTS), the world's leading animal health company, today reported its financial results for the third quarter of 2026.
"Our third-quarter performance was in line with our expectations. Continued pressure in Companion Animal was partially offset by growth in Livestock and Diagnostics, reflecting the breadth of our portfolio," said Kristin Peck, Chief Executive Officer of Zoetis. "We remain focused on defending our position and directing our resources where they can have the greatest impact. And with the scale, expertise, and pipeline to keep setting the pace of innovation in animal health, we are confident in our ability to create long-term value for customers and shareholders."
THIRD QUARTER 2026 FINANCIAL RESULTS
The company reported revenue of $2.4 billion for the third quarter of 2026, a decrease of 1% on a reported and an organic operational1 basis compared with the third quarter of 2025. Net income for the third quarter of 2026 was $591 million, decreasing 18% on a reported basis. Diluted EPS was $1.44, decreasing 12% on a reported basis.
Adjusted net income2 for the third quarter of 2026 was $720 million, decreasing 5% on a reported basis and 7% on an organic operational basis. Adjusted diluted EPS was $1.75, increasing 3% on a reported basis and 1% on an organic operational basis. Adjusted net income for the third quarter of 2026 excludes the net impact of $129 million for purchase accounting adjustments, acquisition and divestiture-related costs and certain significant items.
1 |
THIRD QUARTER 2026 SEGMENT HIGHLIGHTS
Zoetis organizes and manages its commercial operations across two segments: United States (U.S.) and International. Within these segments, the company delivers a diverse portfolio of products for companion animals and livestock, tailored to local trends and customer needs. In the third quarter of 2026:
•Revenue in the U.S. segment was $1.2 billion, decreasing 6% on both a reported and an organic operational basis relative to the third quarter of 2025. Companion animal revenue decreased 8%, reflecting macro-driven price sensitivity and competitive pressure in dermatology, as well as generic competition. Livestock revenue increased 5% on both a reported and organic operational basis in the quarter, supported by strength across cattle, swine and poultry.
•Revenue in the International segment was $1.1 billion, increasing 4% on both a reported and an organic operational basis compared with the third quarter of 2025. Companion animal revenue increased 1% on a reported basis and remained flat on an organic operational basis, led by parasiticides and osteoarthritis (OA) pain, while partially offset by lower sales of key dermatology products. Livestock revenue increased 8% on a reported basis and 9% on an organic operational basis, driven by growth in cattle and fish.
INNOVATION PIPELINE ADVANCEMENTS AND PORTFOLIO UPDATES
Zoetis continued to advance innovation across its diversified portfolio, and remains on track for expected 2026 product approvals, with select approvals anticipated in 2027 now expected in Q4 2026.
Regulatory Approvals and Portfolio Expansion
In October, Zoetis received U.S. Food and Drug Administration (FDA) approval for Convenia® RTU for Dogs, a long-acting antibacterial injection for dogs. This is the second major market approval this year, with both achieved ahead of the expected timelines, and expands Zoetis' portfolio of therapies designed to broaden treatment options for dogs. Convenia RTU for Dogs is expected to be available to veterinarians in the first quarter of 2027.
Zoetis launched Lenivia® for dogs in Great Britain and received Swiss approval for Portela® for cats, expanding access to long-acting osteoarthritis pain relief that can last up to three months with a single injection.
During the quarter, Simparica Trio® received U.S. FDA Emergency Use Authorization (EUA) for the treatment of New World screwworm infestations in dogs and puppies. The authorization adds to Zoetis' existing response, including Dectomax and Dectomax®-CA1 for other species at risk.
2 |
Additional approvals from the quarter include:
•Fostera® PRRS Needle-free microdose was approved in the U.S. and Mexico to help protect pigs against porcine reproductive and respiratory syndrome.
•Vanguard® B Oral received an additional claim in Brazil to help protect dogs against Bordetella bronchiseptica.
•Vanguard® crLyme received an additional claim in Canada to help protect dogs against subclinical arthritis caused by Borrelia burgdorferi.
•Alfaxan® Multidose 4% was approved in Japan and Mexico for sedation of cats.
New Peer-Reviewed Research and Zoetis Medical Hub Launch
•A peer-reviewed study published in Parasites & Vectors found that dogs treated with Simparica Trio had significantly lower average heartworm counts than dogs treated with NexGard® Plus, with few dogs in the Simparica Trio group having adult heartworms at the study's conclusion.
•The study is available through the newly launched Zoetis Medical Hub, which brings together medical expertise and peer-reviewed research.
FULL YEAR 2026 FINANCIAL GUIDANCE
Zoetis is providing updated guidance:
•Narrowed revenue to a range of $9.220 billion to $9.320 billion (organic operational growth of (2)% to (1)%)
•Raised adjusted net income to a range of $2.600 billion to $2.640 billion (organic operational growth of (7)% to (5)%)
•Raised adjusted diluted EPS to a range of $6.25 to $6.35
This guidance reflects foreign exchange rates as of October 20, 2026. Additional details on guidance, including reconciliations of non-GAAP financial measures and the most directly comparable GAAP financial measures, are included in the financial tables and will be discussed on the company's conference call.
WEBCAST & CONFERENCE CALL DETAILS
Zoetis will host a webcast and conference call November 5, 2026, at 8:30 a.m. ET to review third quarter 2026 results, discuss financial guidance and respond to questions from financial analysts. The live webcast and corresponding slides can be accessed by visiting https://investor.zoetis.com/events-presentations. A replay of the webcast will be available following the event.
About Zoetis
Zoetis is the world’s leading animal health company, driven by a singular purpose: to nurture our world and humankind by advancing care for animals. With a legacy of nearly 75 years, Zoetis continues to pioneer ways to predict, prevent, detect, and treat animal illness, supporting veterinarians, livestock
3 |
producers, and pet owners in over 100 countries. We integrate deep scientific expertise, data-driven R&D, advanced manufacturing, and commercial excellence to deliver meaningful innovation across medicines, vaccines, diagnostics, biopharmaceuticals, and digital solutions. Guided by our vision to be the most trusted and valued animal health company, Zoetis is committed to setting new standards for the future of animal care through innovation, customer obsession, and purpose-driven colleagues. To learn more, visit Zoetis.com.
1 Organic operational results (a non-GAAP financial measure) is defined as results excluding the impact of foreign exchange and certain acquisitions and divestitures.
2 Adjusted net income and its components and adjusted diluted earnings per share (non-GAAP financial measures) are defined as reported net income and reported diluted earnings per share, excluding purchase accounting adjustments, acquisition and divestiture-related costs and certain significant items.
DISCLOSURE NOTICES
Forward-Looking Statements: This press release contains forward-looking statements, which reflect the current views of Zoetis with respect to: business plans or prospects, future operating or financial performance, future guidance, future operating models; R&D costs; timing and likelihood of success; expectations regarding products, product approvals or products under development and expected timing of product launches; expectations regarding competing products; expectations regarding financial impact of divestitures; disruptions in our global supply chain; expectations regarding the performance of acquired companies and our ability to integrate new businesses; expectations regarding the financial impact of acquisitions; future use of cash, dividend payments and share repurchases; foreign exchange rates, tax rates, tariffs, changes in tax regimes and laws and any changes thereto; possible impacts of the Fiscal Year Alignment; and other future events. These statements are not guarantees of future performance or actions. Forward-looking statements are subject to risks and uncertainties. If one or more of these risks or uncertainties materialize, or if management's underlying assumptions prove to be incorrect, actual results may differ materially from those contemplated by a forward-looking statement. Forward-looking statements speak only as of the date on which they are made. Zoetis expressly disclaims any obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. A further list and description of risks, uncertainties and other matters can be found in our most recent Annual Report on Form 10-K, including in the sections thereof captioned “Forward-Looking Statements and Factors That May Affect Future Results” and “Item 1A. Risk Factors,” in our Quarterly Reports on Form 10-Q and in our Current Reports on Form 8-K. These filings and subsequent filings are available online at www.sec.gov, www.zoetis.com, or on request from Zoetis.
Use of Non-GAAP Financial Measures: We use non-GAAP financial measures, such as adjusted net income, adjusted diluted earnings per share, operational results (which exclude the impact of foreign exchange) and organic operational results (which exclude the impact of foreign exchange and certain acquisitions and divestitures), to assess and analyze our results and trends and to make financial and operational decisions. We believe these non-GAAP financial measures are also useful to investors because they provide greater transparency regarding our operating performance. The non-GAAP financial measures included in this press release should not be considered alternatives to measurements required by GAAP, such as net income, operating income, and earnings per share, and should not be considered measures of liquidity. These non-GAAP financial measures are unlikely to be comparable with non-GAAP information provided by other companies. Reconciliations of non-GAAP financial measures and the most directly comparable GAAP financial measures are included in the tables accompanying this press release and are posted on our website at www.zoetis.com.
4 |
Internet Posting of Information: We routinely post information that may be important to investors on the 'Investor Relations' section of our website at www.zoetis.com, as well as on LinkedIn, Facebook, X (formerly Twitter) and YouTube. We encourage investors and potential investors to consult our website regularly and to follow us on social media for company news and information.
Media Contacts: | Investor Contacts: | |||||||
| Jennifer Albano | Mathieu Aussermeier | |||||||
| 1-862-399-0810 (o) | 1-862-460-0181 (o) | |||||||
| jennifer.albano@zoetis.com | mathieu.aussermeier@zoetis.com | |||||||
| Laura Panza | Nick Soonthornchai | |||||||
| 1-973-975-5176 (o) | 1-973-443-2792 (o) | |||||||
| laura.panza@zoetis.com | nick.soonthornchai@zoetis.com | |||||||
ZTS-COR
ZTS-IR
ZTS-FIN
5 |
ZOETIS INC.
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(UNAUDITED)
(millions of dollars, except per share data)
| Three Months Ended | Nine Months Ended | ||||||||||||||||||||||||||||||||||
| September 30, | September 30, | ||||||||||||||||||||||||||||||||||
| 2026 | 2025 | % Change | 2026 | 2025 | % Change | ||||||||||||||||||||||||||||||
| Revenue | $ | 2,391 | $ | 2,422 | (1) | $ | 7,121 | $ | 7,094 | — | |||||||||||||||||||||||||
| Costs and expenses: | |||||||||||||||||||||||||||||||||||
| Cost of sales | 698 | 697 | — | 2,012 | 1,979 | 2 | |||||||||||||||||||||||||||||
| Selling, general and administrative expenses | 582 | 582 | — | 1,762 | 1,770 | — | |||||||||||||||||||||||||||||
| Research and development expenses | 174 | 175 | (1) | 527 | 503 | 5 | |||||||||||||||||||||||||||||
| Amortization of intangible assets | 31 | 32 | (3) | 93 | 97 | (4) | |||||||||||||||||||||||||||||
| Restructuring charges and certain acquisition and divestiture-related costs | 43 | 4 | * | 142 | 34 | * | |||||||||||||||||||||||||||||
| Interest expense, net of capitalized interest | 62 | 58 | 7 | 185 | 165 | 12 | |||||||||||||||||||||||||||||
| Other (income)/deductions–net | 72 | (12) | * | 47 | (25) | * | |||||||||||||||||||||||||||||
| Income before provision for taxes on income | 729 | 886 | (18) | 2,353 | 2,571 | (8) | |||||||||||||||||||||||||||||
| Provision for taxes on income | 138 | 165 | (16) | 470 | 522 | (10) | |||||||||||||||||||||||||||||
| Net income before allocation to noncontrolling interests | 591 | 721 | (18) | 1,883 | 2,049 | (8) | |||||||||||||||||||||||||||||
| Less: Net income/(loss) attributable to noncontrolling interests | — | — | * | — | — | * | |||||||||||||||||||||||||||||
| Net income attributable to Zoetis Inc. | $ | 591 | $ | 721 | (18) | $ | 1,883 | $ | 2,049 | (8) | |||||||||||||||||||||||||
| Earnings per share attributable to Zoetis—basic | $ | 1.44 | $ | 1.63 | (12) | $ | 4.51 | $ | 4.60 | (2) | |||||||||||||||||||||||||
| Earnings per share attributable to Zoetis—diluted | $ | 1.44 | $ | 1.63 | (12) | $ | 4.51 | $ | 4.60 | (2) | |||||||||||||||||||||||||
| Weighted-average shares used to calculate earnings per share | |||||||||||||||||||||||||||||||||||
| Basic | 411.6 | 442.9 | 417.1 | 445.2 | |||||||||||||||||||||||||||||||
| Diluted | 411.6 | 443.2 | 417.3 | 445.6 | |||||||||||||||||||||||||||||||
* Calculation not meaningful.
6 |
| ZOETIS INC. | ||||||||||||||||||||||||||||||||
| RECONCILIATION OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATION | ||||||||||||||||||||||||||||||||
| CERTAIN LINE ITEMS | ||||||||||||||||||||||||||||||||
| (UNAUDITED) | ||||||||||||||||||||||||||||||||
| (millions of dollars, except per share data) | ||||||||||||||||||||||||||||||||
| Three Months Ended September 30, 2026 | ||||||||||||||||||||||||||||||||
| GAAP Reported | Purchase Accounting Adjustments | Acquisition and Divestiture- Related Costs(1) | Certain Significant Items(2) | Non-GAAP Adjusted(a) | ||||||||||||||||||||||||||||
| Cost of sales | $ | 698 | $ | (1) | $ | — | $ | (3) | $ | 694 | ||||||||||||||||||||||
| Gross profit | 1,693 | 1 | — | 3 | 1,697 | |||||||||||||||||||||||||||
| Selling, general and administrative expenses | 582 | (3) | — | (8) | 571 | |||||||||||||||||||||||||||
| Amortization of intangible assets | 31 | (27) | — | — | 4 | |||||||||||||||||||||||||||
| Restructuring charges and certain acquisition and divestiture-related costs | 43 | — | (2) | (41) | — | |||||||||||||||||||||||||||
| Other (income)/deductions–net | 72 | — | — | (81) | (9) | |||||||||||||||||||||||||||
| Income before provision for taxes on income | 729 | 31 | 2 | 133 | 895 | |||||||||||||||||||||||||||
| Provision for taxes on income | 138 | 7 | — | 30 | 175 | |||||||||||||||||||||||||||
| Net income attributable to Zoetis | 591 | 24 | 2 | 103 | 720 | |||||||||||||||||||||||||||
| Earnings per common share attributable to Zoetis–diluted | 1.44 | 0.06 | — | 0.25 | 1.75 | |||||||||||||||||||||||||||
| Three Months Ended September 30, 2025 | ||||||||||||||||||||||||||||||||
| GAAP Reported | Purchase Accounting Adjustments | Acquisition and Divestiture- Related Costs(1) | Certain Significant Items(2) | Non-GAAP Adjusted(a) | ||||||||||||||||||||||||||||
| Cost of sales | $ | 697 | $ | (1) | $ | — | $ | (1) | $ | 695 | ||||||||||||||||||||||
| Gross profit | 1,725 | 1 | — | 1 | 1,727 | |||||||||||||||||||||||||||
| Selling, general and administrative expenses | 582 | (3) | — | (7) | 572 | |||||||||||||||||||||||||||
| Research and development expenses | 175 | (1) | — | — | 174 | |||||||||||||||||||||||||||
| Amortization of intangible assets | 32 | (27) | — | — | 5 | |||||||||||||||||||||||||||
| Restructuring charges and certain acquisition and divestiture-related costs | 4 | — | — | (4) | — | |||||||||||||||||||||||||||
| Other (income)/deductions–net | (12) | — | — | 4 | (8) | |||||||||||||||||||||||||||
| Income before provision for taxes on income | 886 | 32 | — | 8 | 926 | |||||||||||||||||||||||||||
| Provision for taxes on income | 165 | 8 | — | (1) | 172 | |||||||||||||||||||||||||||
| Net income attributable to Zoetis | 721 | 24 | — | 9 | 754 | |||||||||||||||||||||||||||
| Earnings per common share attributable to Zoetis–diluted | 1.63 | 0.05 | — | 0.02 | 1.70 | |||||||||||||||||||||||||||
(a) Non-GAAP adjusted net income and its components and non-GAAP adjusted diluted EPS are not, and should not be viewed as, substitutes for U.S. GAAP net income and its components and diluted EPS. Despite the importance of these measures to management in goal setting and performance measurement, non-GAAP adjusted net income and its components and non-GAAP adjusted diluted EPS are non-GAAP financial measures that have no standardized meaning prescribed by U.S. GAAP and, therefore, have limits in their usefulness to investors. Because of the non-standardized definitions, non-GAAP adjusted net income and its components and non-GAAP adjusted diluted EPS (unlike U.S. GAAP net income and its components and diluted EPS) may not be comparable to the calculation of similar measures of other companies. Non-GAAP adjusted net income and its components, and non-GAAP adjusted diluted EPS are presented solely to permit investors to more fully understand how management assesses performance. | ||||||||||||||||||||||||||||||||
| See Notes to Reconciliation of GAAP Reported to Non-GAAP Adjusted Information for notes (1) and (2). | ||||||||||||||||||||||||||||||||
7 |
| ZOETIS INC. | ||||||||||||||||||||||||||||||||
| RECONCILIATION OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATION | ||||||||||||||||||||||||||||||||
| CERTAIN LINE ITEMS | ||||||||||||||||||||||||||||||||
| (UNAUDITED) | ||||||||||||||||||||||||||||||||
| (millions of dollars, except per share data) | ||||||||||||||||||||||||||||||||
| Nine Months Ended September 30, 2026 | ||||||||||||||||||||||||||||||||
| GAAP Reported | Purchase Accounting Adjustments | Acquisition and Divestiture- Related Costs(1) | Certain Significant Items(2) | Non-GAAP Adjusted(a) | ||||||||||||||||||||||||||||
| Cost of sales | $ | 2,012 | $ | (3) | $ | — | $ | (8) | $ | 2,001 | ||||||||||||||||||||||
| Gross profit | 5,109 | 3 | — | 8 | 5,120 | |||||||||||||||||||||||||||
| Selling, general and administrative expenses | 1,762 | (5) | — | (15) | 1,742 | |||||||||||||||||||||||||||
| Research and development expenses | 527 | (1) | — | — | 526 | |||||||||||||||||||||||||||
| Amortization of intangible assets | 93 | (80) | — | — | 13 | |||||||||||||||||||||||||||
| Restructuring charges and certain acquisition and divestiture-related costs | 142 | — | (6) | (136) | — | |||||||||||||||||||||||||||
| Other (income)/deductions–net | 47 | — | — | (82) | (35) | |||||||||||||||||||||||||||
| Income before provision for taxes on income | 2,353 | 89 | 6 | 241 | 2,689 | |||||||||||||||||||||||||||
| Provision for taxes on income | 470 | 20 | 1 | 51 | 542 | |||||||||||||||||||||||||||
| Net income attributable to Zoetis | 1,883 | 69 | 5 | 190 | 2,147 | |||||||||||||||||||||||||||
| Earnings per common share attributable to Zoetis–diluted | 4.51 | 0.17 | 0.01 | 0.45 | 5.14 | |||||||||||||||||||||||||||
| Nine Months Ended September 30, 2025 | ||||||||||||||||||||||||||||||||
| GAAP Reported | Purchase Accounting Adjustments | Acquisition and Divestiture- Related Costs(1) | Certain Significant Items(2) | Non-GAAP Adjusted(a) | ||||||||||||||||||||||||||||
| Cost of sales | $ | 1,979 | $ | (3) | $ | — | $ | (3) | $ | 1,973 | ||||||||||||||||||||||
| Gross profit | 5,115 | 3 | — | 3 | 5,121 | |||||||||||||||||||||||||||
| Selling, general and administrative expenses | 1,770 | (8) | — | (22) | 1,740 | |||||||||||||||||||||||||||
| Research and development expenses | 503 | (2) | — | — | 501 | |||||||||||||||||||||||||||
| Amortization of intangible assets | 97 | (84) | — | — | 13 | |||||||||||||||||||||||||||
| Restructuring charges and certain acquisition and divestiture-related costs | 34 | — | (1) | (33) | — | |||||||||||||||||||||||||||
| Other (income)/deductions–net | (25) | — | — | (4) | (29) | |||||||||||||||||||||||||||
| Income before provision for taxes on income | 2,571 | 97 | 1 | 62 | 2,731 | |||||||||||||||||||||||||||
| Provision for taxes on income | 522 | 23 | — | 8 | 553 | |||||||||||||||||||||||||||
| Net income attributable to Zoetis | 2,049 | 74 | 1 | 54 | 2,178 | |||||||||||||||||||||||||||
| Earnings per common share attributable to Zoetis–diluted | 4.60 | 0.17 | — | 0.12 | 4.89 | |||||||||||||||||||||||||||
(a) Non-GAAP adjusted net income and its components and non-GAAP adjusted diluted EPS are not, and should not be viewed as, substitutes for U.S. GAAP net income and its components and diluted EPS. Despite the importance of these measures to management in goal setting and performance measurement, non-GAAP adjusted net income and its components and non-GAAP adjusted diluted EPS are non-GAAP financial measures that have no standardized meaning prescribed by U.S. GAAP and, therefore, have limits in their usefulness to investors. Because of the non-standardized definitions, non-GAAP adjusted net income and its components and non-GAAP adjusted diluted EPS (unlike U.S. GAAP net income and its components and diluted EPS) may not be comparable to the calculation of similar measures of other companies. Non-GAAP adjusted net income and its components, and non-GAAP adjusted diluted EPS are presented solely to permit investors to more fully understand how management assesses performance. | ||||||||||||||||||||||||||||||||
| See Notes to Reconciliation of GAAP Reported to Non-GAAP Adjusted Information for notes (1) and (2). | ||||||||||||||||||||||||||||||||
8 |
ZOETIS INC.
NOTES TO RECONCILIATION OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATION
CERTAIN LINE ITEMS
(UNAUDITED)
(millions of dollars)
(1) Acquisition and divestiture-related costs include the following:
| Three Months Ended | Nine Months Ended | ||||||||||||||||||||||
| September 30, | September 30, | ||||||||||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||||||||||
Acquisition-related costs(a) | $ | 2 | $ | — | $ | 6 | $ | 1 | |||||||||||||||
| Total acquisition and divestiture-related costs—pre-tax | 2 | — | 6 | 1 | |||||||||||||||||||
Income taxes(b) | — | — | 1 | — | |||||||||||||||||||
| Total acquisition and divestiture-related costs—net of tax | $ | 2 | $ | — | $ | 5 | $ | 1 | |||||||||||||||
(a) Acquisition-related costs represent external, incremental costs that directly relate to transacting and integrating businesses, included in Restructuring charges and certain acquisition and divestiture-related costs.
(b) Included in Provision for taxes on income. Income taxes include the tax effect of the associated pre-tax amounts, calculated by determining the jurisdictional location of the pre-tax amounts and applying that jurisdiction's applicable tax rate.
(2) Certain significant items include the following:
| Three Months Ended | Nine Months Ended | ||||||||||||||||||||||
| September 30, | September 30, | ||||||||||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||||||||||
Other restructuring charges and cost-reduction/productivity initiatives(a) | $ | 30 | $ | 4 | $ | 125 | $ | 11 | |||||||||||||||
Business process transformation program(b) | 7 | 8 | 18 | 26 | |||||||||||||||||||
Certain asset impairment charges(c) | 89 | — | 89 | 27 | |||||||||||||||||||
Net loss on sale of business(d) | — | — | — | 3 | |||||||||||||||||||
| Other | 7 | (4) | 9 | (5) | |||||||||||||||||||
| Total certain significant items—pre-tax | 133 | 8 | 241 | 62 | |||||||||||||||||||
Income taxes(e) | 30 | (1) | 51 | 8 | |||||||||||||||||||
| Total certain significant items—net of tax | $ | 103 | $ | 9 | $ | 190 | $ | 54 | |||||||||||||||
(a) For the three and nine months ended September 30, 2026, primarily driven by employee termination costs under a comprehensive cost and productivity program, with the nine-month period also reflecting employee termination costs from additional organizational structure refinements, included in Restructuring charges and certain acquisition and divestiture-related costs..
For the three and nine months ended September 30, 2025, primarily related to a transition from internal to external innovation and manufacturing of certain products and the closure of a related site, included in Restructuring charges and certain acquisition and divestiture-related costs.
(b) Represents costs related to our multi-year business process transformation program, which includes the implementation of a new enterprise resource planning (ERP) system, related digital technology solutions and other related costs, included in Selling, general and administrative expenses and Cost of sales. This comprehensive program is a major global and cross-functional company-wide effort that we believe will transform how we work across our business and contribute to all of our strategic priorities. Due to the nature, scope and magnitude of this investment, these costs are incremental transformational costs that are far in excess of the historical normal level of spending to support operations and are not expected to recur in the foreseeable future.
(c) For the three and nine months ended September 30, 2026, represents impairment charges on in-process research and development assets, acquired from PetMedix in 2023, resulting from updated estimates of development and commercial assumptions, included in Other (income)/deductions–net, as well as charges related to the exit of certain sites, included in Restructuring charges and certain acquisition and divestiture-related costs.
For the three and nine months ended September 30, 2025, represents certain asset impairment charges related to a transition from internal to external innovation and manufacturing of certain products and the closure of a related site, included in Restructuring charges and certain acquisition and divestiture-related costs, as well as charges related to our aquaculture product portfolio, included in Other (income)/deductions–net.
(d) Represents a net loss related to the sale of our medicated feed additive product portfolio, certain water soluble products and related assets sold in 2024, included in Other (income)/deductions–net.
(e) Included in Provision for taxes on income. Income taxes include the tax effect of the associated pre-tax amounts, calculated by determining the jurisdictional location of the pre-tax amounts and applying that jurisdiction's applicable tax rate.
9 |
ZOETIS INC.
ADJUSTED SELECTED COSTS, EXPENSES AND INCOME(a)
(UNAUDITED)
(millions of dollars)
| Three Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||
| September 30, | % Change | |||||||||||||||||||||||||||||||||||||||||||||||||
| 2026 | 2025 | Reported Change | Foreign Exchange | Operational(b) | Divestitures | Organic Operational(c) | ||||||||||||||||||||||||||||||||||||||||||||
| Adjusted cost of sales | $ | 694 | $ | 695 | — | % | — | % | — | % | ||||||||||||||||||||||||||||||||||||||||
| as a percent of revenue | 29.0 | % | 28.7 | % | NA | NA | NA | |||||||||||||||||||||||||||||||||||||||||||
| Adjusted SG&A expenses | 571 | 572 | — | % | — | % | — | % | ||||||||||||||||||||||||||||||||||||||||||
| Adjusted R&D expenses | 174 | 174 | — | % | — | % | — | % | ||||||||||||||||||||||||||||||||||||||||||
| Adjusted net income | 720 | 754 | (5) | % | 2 | % | (7) | % | — | % | (7) | % | ||||||||||||||||||||||||||||||||||||||
| Nine Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||
| September 30, | % Change | |||||||||||||||||||||||||||||||||||||||||||||||||
| 2026 | 2025 | Reported Change | Foreign Exchange | Operational(b) | Divestitures | Organic Operational(c) | ||||||||||||||||||||||||||||||||||||||||||||
| Adjusted cost of sales | $ | 2,001 | $ | 1,973 | 1 | % | 3 | % | (2) | % | ||||||||||||||||||||||||||||||||||||||||
| as a percent of revenue | 28.1 | % | 27.8 | % | NA | NA | NA | |||||||||||||||||||||||||||||||||||||||||||
| Adjusted SG&A expenses | 1,742 | 1,740 | — | % | 1 | % | (1) | % | ||||||||||||||||||||||||||||||||||||||||||
| Adjusted R&D expenses | 526 | 501 | 5 | % | 1 | % | 4 | % | ||||||||||||||||||||||||||||||||||||||||||
| Adjusted net income | 2,147 | 2,178 | (1) | % | 2 | % | (3) | % | — | % | (3) | % | ||||||||||||||||||||||||||||||||||||||
(a) Adjusted cost of sales, adjusted selling, general, and administrative (SG&A) expenses, adjusted research and development (R&D) expenses, and adjusted net income (non-GAAP financial measures) are defined as the corresponding reported U.S. GAAP income statement line items excluding purchase accounting adjustments, acquisition and divestiture-related costs and certain significant items. These adjusted income statement line item measures are not, and should not be viewed as, substitutes for the corresponding U.S. GAAP line items. The corresponding GAAP line items and reconciliations of reported to adjusted information are provided in Condensed Consolidated Statements of Income and Reconciliation of GAAP Reported to Non-GAAP Adjusted Information.
(b) Operational results (a non-GAAP financial measure) is defined as results excluding the impact of foreign exchange.
(c) Organic operational results (a non-GAAP financial measure) is defined as results excluding the impact of foreign exchange and certain acquisitions and divestitures.
10 |
ZOETIS INC.
2026 GUIDANCE
| Selected Line Items (millions of dollars, except per share amounts) | Full Year 2026 as of November 5, 2026 | Full Year 2026 as of August 6, 2026 (Prior Guidance) | ||||||
| Revenue | $9,220 to $9,320 | $9,120 to $9,320 | ||||||
Organic operational results(a) | (2)% to (1)% | (3)% to (1)% | ||||||
Adjusted cost of sales as a percentage of revenue(b) | Approximately 29.0% | Approximately 29.0% | ||||||
Adjusted SG&A expenses(b) | $2,340 to $2,370 | $2,330 to $2,380 | ||||||
Adjusted R&D expenses(b) | $705 to $715 | $720 to $730 | ||||||
Adjusted interest expense and other (income)/deductions-net(b) | Approximately $215 | Approximately $215 | ||||||
Effective tax rate on adjusted income(b) | Approximately 20% | Approximately 20.5% | ||||||
Adjusted diluted EPS(b) | $6.25 to $6.35 | $6.15 to $6.25 | ||||||
Adjusted net income(b) | $2,600 to $2,640 | $2,570 to $2,620 | ||||||
Organic operational results(a)(c) | (7)% to (5)% | (9)% to (5)% | ||||||
Certain significant items and acquisition and divestiture-related costs(d) | Approximately $210 | Approximately $150 | ||||||
| Reported diluted EPS | $5.50 to $5.60 | $5.55 to $5.65 | ||||||
The guidance reflects foreign exchange rates as of October 20, 2026.
Reconciliations of 2026 reported guidance to 2026 adjusted guidance follows:
| (millions of dollars, except per share amounts) | Reported | Certain significant items and acquisition and divestiture-related costs(d) | Purchase accounting | Adjusted(b) | ||||||||||
| Cost of sales as a percentage of revenue | ~ 29.1% | ~ (0.1%) | ~ 29.0% | |||||||||||
| SG&A expenses | $2,373 to $2,403 | ~ $(22) | ~ $(11) | $2,340 to $2,370 | ||||||||||
| R&D expenses | $707 to $717 | ~ $(2) | $705 to $715 | |||||||||||
| Interest expense and other (income)/deductions-net | ~ $215 | ~ $215 | ||||||||||||
| Effective tax rate | ~ 20% | ~ 20% | ||||||||||||
| Diluted EPS | $5.50 to $5.60 | ~ $0.53 | ~ $0.22 | $6.25 to $6.35 | ||||||||||
| Net income attributable to Zoetis | $2,300 to $2,340 | ~ $210 | ~ $90 | $2,600 to $2,640 | ||||||||||
(a) Organic operational results (a non-GAAP financial measure) excludes the impact of foreign exchange and certain acquisitions and divestitures.
(b) Adjusted net income and its components and adjusted diluted EPS are defined as reported U.S. GAAP net income and its components and reported diluted EPS excluding purchase accounting adjustments, acquisition and divestiture-related costs and certain significant items. Adjusted cost of sales, adjusted SG&A expenses, adjusted R&D expenses, and adjusted interest expense and other (income)/deductions-net are income statement line items prepared on the same basis, and, therefore, components of the overall adjusted income measure. Despite the importance of these measures to management in goal setting and performance measurement, adjusted net income and its components and adjusted diluted EPS are non-GAAP financial measures that have no standardized meaning prescribed by U.S. GAAP and, therefore, have limits in their usefulness to investors. Because of the non-standardized definitions, adjusted net income and its components and adjusted diluted EPS (unlike U.S. GAAP net income and its components and diluted EPS) may not be comparable to the calculation of similar measures of other companies. Adjusted net income and its components and adjusted diluted EPS are presented solely to permit investors to more fully understand how management assesses performance. Adjusted net income and its components and adjusted diluted EPS are not, and should not be viewed as, substitutes for U.S. GAAP net income and its components and diluted EPS.
(c) We do not provide a reconciliation of forward-looking non-GAAP adjusted net income operational results to the most directly comparable U.S. GAAP reported financial measure because we are unable to calculate with reasonable certainty the foreign exchange impact of unusual gains and losses, acquisition and divestiture-related expenses, potential future asset impairments and other certain significant items, without unreasonable effort. The foreign exchange impacts of these items are uncertain, depend on various factors, and could have a material impact on U.S. GAAP reported results for the guidance period.
(d) Primarily includes certain nonrecurring costs related to acquisitions, divestitures and other charges.
11 |
ZOETIS INC. CONSOLIDATED REVENUE BY SEGMENT(a) AND SPECIES (UNAUDITED) (millions of dollars) | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Three Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||
| September 30, | % Change | |||||||||||||||||||||||||||||||||||||||||||||||||
| 2026 | 2025 | Reported Change | Foreign Exchange | Operational(b) | Divestitures | Organic Operational(c) | ||||||||||||||||||||||||||||||||||||||||||||
| Revenue: | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Companion Animal | $ | 1,565 | $ | 1,650 | (5) | % | — | % | (5) | % | — | % | (5) | % | ||||||||||||||||||||||||||||||||||||
| Livestock | 797 | 746 | 7 | % | 1 | % | 6 | % | (1) | % | 7 | % | ||||||||||||||||||||||||||||||||||||||
| Contract Manufacturing & Human Health | 29 | 26 | 12 | % | (3) | % | 15 | % | — | % | 15 | % | ||||||||||||||||||||||||||||||||||||||
| Total Revenue | $ | 2,391 | $ | 2,422 | (1) | % | 1 | % | (2) | % | (1) | % | (1) | % | ||||||||||||||||||||||||||||||||||||
| U.S.: | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Companion Animal | $ | 980 | $ | 1,069 | (8) | % | — | % | (8) | % | — | % | (8) | % | ||||||||||||||||||||||||||||||||||||
| Livestock | 266 | 253 | 5 | % | — | % | 5 | % | — | % | 5 | % | ||||||||||||||||||||||||||||||||||||||
| Total U.S. Revenue | $ | 1,246 | $ | 1,322 | (6) | % | — | % | (6) | % | — | % | (6) | % | ||||||||||||||||||||||||||||||||||||
| International: | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Companion Animal | $ | 585 | $ | 581 | 1 | % | 1 | % | — | % | — | % | — | % | ||||||||||||||||||||||||||||||||||||
| Livestock | 531 | 493 | 8 | % | 2 | % | 6 | % | (3) | % | 9 | % | ||||||||||||||||||||||||||||||||||||||
| Total International Revenue | $ | 1,116 | $ | 1,074 | 4 | % | 1 | % | 3 | % | (1) | % | 4 | % | ||||||||||||||||||||||||||||||||||||
| Companion Animal: | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Dogs and Cats | $ | 1,492 | $ | 1,581 | (6) | % | — | % | (6) | % | ||||||||||||||||||||||||||||||||||||||||
| Horses | 73 | 69 | 6 | % | — | % | 6 | % | ||||||||||||||||||||||||||||||||||||||||||
| Total Companion Animal Revenue | $ | 1,565 | $ | 1,650 | (5) | % | — | % | (5) | % | ||||||||||||||||||||||||||||||||||||||||
| Livestock: | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Cattle | $ | 439 | $ | 415 | 6 | % | 1 | % | 5 | % | ||||||||||||||||||||||||||||||||||||||||
| Swine | 120 | 116 | 3 | % | 1 | % | 2 | % | ||||||||||||||||||||||||||||||||||||||||||
| Poultry | 108 | 106 | 2 | % | (1) | % | 3 | % | ||||||||||||||||||||||||||||||||||||||||||
| Fish | 98 | 80 | 23 | % | 5 | % | 18 | % | ||||||||||||||||||||||||||||||||||||||||||
| Sheep and other | 32 | 29 | 10 | % | 4 | % | 6 | % | ||||||||||||||||||||||||||||||||||||||||||
| Total Livestock Revenue | $ | 797 | $ | 746 | 7 | % | 1 | % | 6 | % | ||||||||||||||||||||||||||||||||||||||||
| (a) For a description of each segment, see Zoetis' most recent Annual Report on Form 10-K. | ||||||||||||||||||||||||||||||||||||||||||||||||||
| (b) Operational revenue results (a non-GAAP financial measure) is defined as revenue results excluding the impact of foreign exchange. | ||||||||||||||||||||||||||||||||||||||||||||||||||
(c) Organic operational revenue results (a non-GAAP financial measure) is defined as revenue results excluding the impact of foreign exchange and certain acquisitions and divestitures. | ||||||||||||||||||||||||||||||||||||||||||||||||||
12 |
ZOETIS INC. CONSOLIDATED REVENUE BY SEGMENT(a) AND SPECIES (UNAUDITED) (millions of dollars) | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Nine Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||
| September 30, | % Change | |||||||||||||||||||||||||||||||||||||||||||||||||
| 2026 | 2025 | Reported Change | Foreign Exchange | Operational(b) | Divestitures | Organic Operational(c) | ||||||||||||||||||||||||||||||||||||||||||||
| Revenue: | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Companion Animal | $ | 4,792 | $ | 4,981 | (4) | % | 1 | % | (5) | % | — | % | (5) | % | ||||||||||||||||||||||||||||||||||||
| Livestock | 2,248 | 2,024 | 11 | % | 3 | % | 8 | % | (2) | % | 10 | % | ||||||||||||||||||||||||||||||||||||||
| Contract Manufacturing & Human Health | 81 | 89 | (9) | % | — | % | (9) | % | — | % | (9) | % | ||||||||||||||||||||||||||||||||||||||
| Total Revenue | $ | 7,121 | $ | 7,094 | — | % | 1 | % | (1) | % | — | % | (1) | % | ||||||||||||||||||||||||||||||||||||
| U.S.: | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Companion Animal | $ | 2,889 | $ | 3,218 | (10) | % | — | % | (10) | % | — | % | (10) | % | ||||||||||||||||||||||||||||||||||||
| Livestock | 713 | 643 | 11 | % | — | % | 11 | % | — | % | 11 | % | ||||||||||||||||||||||||||||||||||||||
| Total U.S. Revenue | $ | 3,602 | $ | 3,861 | (7) | % | — | % | (7) | % | — | % | (7) | % | ||||||||||||||||||||||||||||||||||||
| International: | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Companion Animal | $ | 1,903 | $ | 1,763 | 8 | % | 4 | % | 4 | % | — | % | 4 | % | ||||||||||||||||||||||||||||||||||||
| Livestock | 1,535 | 1,381 | 11 | % | 4 | % | 7 | % | (2) | % | 9 | % | ||||||||||||||||||||||||||||||||||||||
| Total International Revenue | $ | 3,438 | $ | 3,144 | 9 | % | 4 | % | 5 | % | (1) | % | 6 | % | ||||||||||||||||||||||||||||||||||||
| Companion Animal: | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Dogs and Cats | $ | 4,569 | $ | 4,777 | (4) | % | 2 | % | (6) | % | ||||||||||||||||||||||||||||||||||||||||
| Horses | 223 | 204 | 9 | % | 2 | % | 7 | % | ||||||||||||||||||||||||||||||||||||||||||
| Total Companion Animal Revenue | $ | 4,792 | $ | 4,981 | (4) | % | 1 | % | (5) | % | ||||||||||||||||||||||||||||||||||||||||
| Livestock: | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Cattle | $ | 1,221 | $ | 1,079 | 13 | % | 2 | % | 11 | % | ||||||||||||||||||||||||||||||||||||||||
| Swine | 360 | 339 | 6 | % | 3 | % | 3 | % | ||||||||||||||||||||||||||||||||||||||||||
| Poultry | 341 | 316 | 8 | % | 1 | % | 7 | % | ||||||||||||||||||||||||||||||||||||||||||
| Fish | 247 | 216 | 14 | % | 6 | % | 8 | % | ||||||||||||||||||||||||||||||||||||||||||
| Sheep and other | 79 | 74 | 7 | % | 6 | % | 1 | % | ||||||||||||||||||||||||||||||||||||||||||
| Total Livestock Revenue | $ | 2,248 | $ | 2,024 | 11 | % | 3 | % | 8 | % | ||||||||||||||||||||||||||||||||||||||||
| (a) For a description of each segment, see Zoetis' most recent Annual Report on Form 10-K. | ||||||||||||||||||||||||||||||||||||||||||||||||||
| (b) Operational revenue results (a non-GAAP financial measure) is defined as revenue results excluding the impact of foreign exchange. | ||||||||||||||||||||||||||||||||||||||||||||||||||
(c) Organic operational revenue results (a non-GAAP financial measure) is defined as revenue results excluding the impact of foreign exchange and certain acquisitions and divestitures. | ||||||||||||||||||||||||||||||||||||||||||||||||||
13 |
ZOETIS INC.
CONSOLIDATED REVENUE BY KEY INTERNATIONAL MARKETS
(UNAUDITED)
(millions of dollars)
| Three Months Ended | |||||||||||||||||||||||||||||||||||||||||
| September 30, | % Change | ||||||||||||||||||||||||||||||||||||||||
| 2026 | 2025 | Reported Change | Foreign Exchange | Divestitures | Organic Operational(a) | ||||||||||||||||||||||||||||||||||||
| Total International | $ | 1,116 | $ | 1,074 | 4 | % | 1 | % | (1) | % | 4 | % | |||||||||||||||||||||||||||||
| Australia | 104 | 92 | 13 | % | 9 | % | — | % | 4 | % | |||||||||||||||||||||||||||||||
| Brazil | 114 | 105 | 9 | % | 6 | % | — | % | 3 | % | |||||||||||||||||||||||||||||||
| Canada | 70 | 76 | (8) | % | — | % | (10) | % | 2 | % | |||||||||||||||||||||||||||||||
| Chile | 34 | 33 | 3 | % | (2) | % | — | % | 5 | % | |||||||||||||||||||||||||||||||
| China | 61 | 51 | 20 | % | 6 | % | — | % | 14 | % | |||||||||||||||||||||||||||||||
| France | 37 | 35 | 6 | % | (3) | % | (1) | % | 10 | % | |||||||||||||||||||||||||||||||
| Germany | 51 | 62 | (18) | % | (2) | % | (1) | % | (15) | % | |||||||||||||||||||||||||||||||
| Italy | 30 | 34 | (12) | % | (2) | % | — | % | (10) | % | |||||||||||||||||||||||||||||||
| Japan | 26 | 34 | (24) | % | (6) | % | — | % | (18) | % | |||||||||||||||||||||||||||||||
| Mexico | 49 | 42 | 17 | % | 10 | % | — | % | 7 | % | |||||||||||||||||||||||||||||||
| Spain | 37 | 36 | 3 | % | (2) | % | (2) | % | 7 | % | |||||||||||||||||||||||||||||||
| United Kingdom | 75 | 79 | (5) | % | 1 | % | (2) | % | (4) | % | |||||||||||||||||||||||||||||||
| Other developed markets | 183 | 165 | 11 | % | 1 | % | — | % | 10 | % | |||||||||||||||||||||||||||||||
| Other emerging markets | 245 | 230 | 7 | % | (2) | % | (1) | % | 10 | % | |||||||||||||||||||||||||||||||
| Nine Months Ended | |||||||||||||||||||||||||||||||||||||||||
| September 30, | % Change | ||||||||||||||||||||||||||||||||||||||||
| 2026 | 2025 | Reported Change | Foreign Exchange | Divestitures | Organic Operational(a) | ||||||||||||||||||||||||||||||||||||
| Total International | $ | 3,438 | $ | 3,144 | 9 | % | 4 | % | (1) | % | 6 | % | |||||||||||||||||||||||||||||
| Australia | 287 | 254 | 13 | % | 10 | % | — | % | 3 | % | |||||||||||||||||||||||||||||||
| Brazil | 307 | 279 | 10 | % | 9 | % | — | % | 1 | % | |||||||||||||||||||||||||||||||
| Canada | 215 | 217 | (1) | % | 1 | % | (7) | % | 5 | % | |||||||||||||||||||||||||||||||
| Chile | 106 | 102 | 4 | % | 2 | % | (1) | % | 3 | % | |||||||||||||||||||||||||||||||
| China | 186 | 173 | 8 | % | 6 | % | — | % | 2 | % | |||||||||||||||||||||||||||||||
| France | 114 | 116 | (2) | % | 3 | % | (1) | % | (4) | % | |||||||||||||||||||||||||||||||
| Germany | 179 | 174 | 3 | % | 4 | % | (1) | % | — | % | |||||||||||||||||||||||||||||||
| Italy | 109 | 101 | 8 | % | 5 | % | (1) | % | 4 | % | |||||||||||||||||||||||||||||||
| Japan | 102 | 109 | (6) | % | (6) | % | (1) | % | 1 | % | |||||||||||||||||||||||||||||||
| Mexico | 144 | 116 | 24 | % | 14 | % | — | % | 10 | % | |||||||||||||||||||||||||||||||
| Spain | 120 | 105 | 14 | % | 4 | % | (2) | % | 12 | % | |||||||||||||||||||||||||||||||
| United Kingdom | 225 | 234 | (4) | % | 2 | % | (1) | % | (5) | % | |||||||||||||||||||||||||||||||
| Other developed markets | 539 | 473 | 14 | % | 5 | % | (1) | % | 10 | % | |||||||||||||||||||||||||||||||
| Other emerging markets | 805 | 691 | 16 | % | — | % | (1) | % | 17 | % | |||||||||||||||||||||||||||||||
(a) Organic operational revenue results (a non-GAAP financial measure) is defined as revenue results excluding the impact of foreign exchange and certain acquisitions and divestitures.
14 |
ZOETIS INC. SEGMENT(a) EARNINGS (UNAUDITED) (millions of dollars) | |||||||||||||||||||||||||||||||||||
| Three Months Ended | |||||||||||||||||||||||||||||||||||
| September 30, | % Change | ||||||||||||||||||||||||||||||||||
| 2026 | 2025 | Reported Change | Foreign Exchange | Operational(b) | |||||||||||||||||||||||||||||||
| U.S.: | |||||||||||||||||||||||||||||||||||
| Revenue | $ | 1,246 | $ | 1,322 | (6) | % | — | % | (6) | % | |||||||||||||||||||||||||
| Cost of Sales | 222 | 222 | — | % | — | % | — | % | |||||||||||||||||||||||||||
| Gross Profit | 1,024 | 1,100 | (7) | % | — | % | (7) | % | |||||||||||||||||||||||||||
| Gross Margin | 82.2 | % | 83.2 | % | |||||||||||||||||||||||||||||||
| Operating Expenses | 194 | 201 | (3) | % | — | % | (3) | % | |||||||||||||||||||||||||||
| Other (income)/deductions-net | — | — | * | * | * | ||||||||||||||||||||||||||||||
| U.S. Earnings | $ | 830 | $ | 899 | (8) | % | — | % | (8) | % | |||||||||||||||||||||||||
| International: | |||||||||||||||||||||||||||||||||||
| Revenue | $ | 1,116 | $ | 1,074 | 4 | % | 1 | % | 3 | % | |||||||||||||||||||||||||
| Cost of Sales | 347 | 342 | 1 | % | — | % | 1 | % | |||||||||||||||||||||||||||
| Gross Profit | 769 | 732 | 5 | % | 2 | % | 3 | % | |||||||||||||||||||||||||||
| Gross Margin | 68.9 | % | 68.2 | % | |||||||||||||||||||||||||||||||
| Operating Expenses | 169 | 169 | — | % | 1 | % | (1) | % | |||||||||||||||||||||||||||
| Other (income)/deductions-net | — | — | * | * | * | ||||||||||||||||||||||||||||||
| International Earnings | $ | 600 | $ | 563 | 7 | % | 2 | % | 5 | % | |||||||||||||||||||||||||
| Total Reportable Segments | $ | 1,430 | $ | 1,462 | (2) | % | 1 | % | (3) | % | |||||||||||||||||||||||||
Other business activities(c) | (134) | (143) | (6) | % | |||||||||||||||||||||||||||||||
| Reconciling Items: | |||||||||||||||||||||||||||||||||||
Corporate(d) | (303) | (304) | — | % | |||||||||||||||||||||||||||||||
Purchase accounting adjustments(e) | (31) | (32) | (3) | % | |||||||||||||||||||||||||||||||
Acquisition and divestiture-related costs(f) | (2) | — | * | ||||||||||||||||||||||||||||||||
Certain significant items(g) | (133) | (8) | * | ||||||||||||||||||||||||||||||||
Other unallocated(h) | (98) | (89) | 10 | % | |||||||||||||||||||||||||||||||
Total Earnings(i) | $ | 729 | $ | 886 | (18) | % | |||||||||||||||||||||||||||||
| (a) For a description of each segment, see Zoetis' most recent Annual Report on Form 10-K. | |||||||||||||||||||||||||||||||||||
| (b) Operational results (a non-GAAP financial measure) is defined as results excluding the impact of foreign exchange. | |||||||||||||||||||||||||||||||||||
| (c) Other business activities includes the research and development costs managed by our research and development organization, as well as our contract manufacturing business and human health business. | |||||||||||||||||||||||||||||||||||
| (d) Corporate includes, among other things, certain costs associated with information technology, administration expenses, interest income and expense, certain compensation costs and other costs not charged to our operating segments. | |||||||||||||||||||||||||||||||||||
| (e) Purchase accounting adjustments include certain charges related to the amortization of fair value adjustments to inventory, intangible assets and property, plant and equipment not charged to our operating segments. | |||||||||||||||||||||||||||||||||||
| (f) Acquisition and divestiture-related costs include costs associated with acquiring and integrating newly acquired businesses, such as transaction costs and integration costs, as well as costs associated with divesting and disintegrating a portion of our business. | |||||||||||||||||||||||||||||||||||
| (g) Certain significant items includes substantive, unusual items that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis. Such items primarily include certain asset impairment charges, restructuring charges and implementation costs associated with cost-reduction/productivity initiatives that are not associated with an acquisition, costs related to our business process transformation program, as well as the impact of divestiture gains and losses. | |||||||||||||||||||||||||||||||||||
| (h) Includes overhead expenses associated with our global manufacturing and supply operations not directly attributable to an operating segment, as well as certain procurement costs. | |||||||||||||||||||||||||||||||||||
| (i) Defined as income before provision for taxes on income. | |||||||||||||||||||||||||||||||||||
| * Calculation not meaningful. | |||||||||||||||||||||||||||||||||||
15 |
ZOETIS INC. SEGMENT(a) EARNINGS (UNAUDITED) (millions of dollars) | |||||||||||||||||||||||||||||||||||
| Nine Months Ended | |||||||||||||||||||||||||||||||||||
| September 30, | % Change | ||||||||||||||||||||||||||||||||||
| 2026 | 2025 | Reported Change | Foreign Exchange | Operational(b) | |||||||||||||||||||||||||||||||
| U.S.: | |||||||||||||||||||||||||||||||||||
| Revenue | $ | 3,602 | $ | 3,861 | (7) | % | — | % | (7) | % | |||||||||||||||||||||||||
| Cost of Sales | 630 | 629 | — | % | — | % | — | % | |||||||||||||||||||||||||||
| Gross Profit | 2,972 | 3,232 | (8) | % | — | % | (8) | % | |||||||||||||||||||||||||||
| Gross Margin | 82.5 | % | 83.7 | % | |||||||||||||||||||||||||||||||
| Operating Expenses | 608 | 624 | (3) | % | — | % | (3) | % | |||||||||||||||||||||||||||
| Other (income)/deductions-net | — | — | * | * | * | ||||||||||||||||||||||||||||||
| U.S. Earnings | $ | 2,364 | $ | 2,608 | (9) | % | — | % | (9) | % | |||||||||||||||||||||||||
| International: | |||||||||||||||||||||||||||||||||||
| Revenue | $ | 3,438 | $ | 3,144 | 9 | % | 4 | % | 5 | % | |||||||||||||||||||||||||
| Cost of Sales | 1,021 | 958 | 7 | % | 5 | % | 2 | % | |||||||||||||||||||||||||||
| Gross Profit | 2,417 | 2,186 | 11 | % | 4 | % | 7 | % | |||||||||||||||||||||||||||
| Gross Margin | 70.3 | % | 69.5 | % | |||||||||||||||||||||||||||||||
| Operating Expenses | 516 | 503 | 3 | % | 4 | % | (1) | % | |||||||||||||||||||||||||||
| Other (income)/deductions-net | 1 | 1 | — | % | * | * | |||||||||||||||||||||||||||||
| International Earnings | $ | 1,900 | $ | 1,682 | 13 | % | 4 | % | 9 | % | |||||||||||||||||||||||||
| Total Reportable Segments | $ | 4,264 | $ | 4,290 | (1) | % | 1 | % | (2) | % | |||||||||||||||||||||||||
Other business activities(c) | (410) | (405) | 1 | % | |||||||||||||||||||||||||||||||
| Reconciling Items: | |||||||||||||||||||||||||||||||||||
Corporate(d) | (933) | (906) | 3 | % | |||||||||||||||||||||||||||||||
Purchase accounting adjustments(e) | (89) | (97) | (8) | % | |||||||||||||||||||||||||||||||
Acquisition and divestiture-related costs(f) | (6) | (1) | * | ||||||||||||||||||||||||||||||||
Certain significant items(g) | (241) | (62) | * | ||||||||||||||||||||||||||||||||
Other unallocated(h) | (232) | (248) | (6) | % | |||||||||||||||||||||||||||||||
Total Earnings(i) | $ | 2,353 | $ | 2,571 | (8) | % | |||||||||||||||||||||||||||||
| (a) For a description of each segment, see Zoetis' most recent Annual Report on Form 10-K. | |||||||||||||||||||||||||||||||||||
| (b) Operational results (a non-GAAP financial measure) is defined as results excluding the impact of foreign exchange. | |||||||||||||||||||||||||||||||||||
| (c) Other business activities includes the research and development costs managed by our research and development organization, as well as our contract manufacturing business and human health business. | |||||||||||||||||||||||||||||||||||
| (d) Corporate includes, among other things, certain costs associated with information technology, administration expenses, interest income and expense, certain compensation costs and other costs not charged to our operating segments. | |||||||||||||||||||||||||||||||||||
| (e) Purchase accounting adjustments include certain charges related to the amortization of fair value adjustments to inventory, intangible assets and property, plant and equipment not charged to our operating segments. | |||||||||||||||||||||||||||||||||||
| (f) Acquisition and divestiture-related costs include costs associated with acquiring and integrating newly acquired businesses, such as transaction costs and integration costs, as well as costs associated with divesting and disintegrating a portion of our business. | |||||||||||||||||||||||||||||||||||
| (g) Certain significant items includes substantive, unusual items that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis. Such items primarily include certain asset impairment charges, restructuring charges and implementation costs associated with cost-reduction/productivity initiatives that are not associated with an acquisition, costs related to our business process transformation program, as well as the impact of divestiture gains and losses. | |||||||||||||||||||||||||||||||||||
| (h) Includes overhead expenses associated with our global manufacturing and supply operations not directly attributable to an operating segment, as well as certain procurement costs. | |||||||||||||||||||||||||||||||||||
| (i) Defined as income before provision for taxes on income. | |||||||||||||||||||||||||||||||||||
| * Calculation not meaningful. | |||||||||||||||||||||||||||||||||||
16 |